Lower-priority studies not included in the systematic review of clinical effectiveness or considered for the network meta-analyses (n = 28)

Matthew Walton; Ros Wade; Lindsay Claxton; Sahar Sharif-Hurst; Melissa Harden; Jai Patel; Ian Rowe; Robert Hodgson; Alison Eastwood

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Walton M, Wade R, Claxton L, et al. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation. Southampton (UK): NIHR Journals Library; 2020 Sep. (Health Technology Assessment, No. 24.48.)

Cover of Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation

Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.

Show details

Contents

< Prev Next >

Appendix 7Lower-priority studies not included in the systematic review of clinical effectiveness or considered for the network meta-analyses (n = 28)

Study (first author and year)	Intervention	Comparator	Reason for not including in the systematic review
Moroz 2001⁵³	SIR-Spheres plus hepatic arterial chemotherapy	Hepatic arterial chemotherapy	Clinical advice that hepatic arterial chemotherapy is not applicable to current UK practice
Pellerito 2013⁵⁵	SIR-Spheres	131-iodine Lipiodol	Clinical advice that 131-iodine Lipiodol is not applicable to current UK practice
Steel 2004⁵²	TheraSphere	Hepatic arterial infusion of cisplatin	Clinical advice that hepatic arterial infusion of cisplatin is not applicable to current UK practice
Maccauro 2016⁵⁴	Standard-dose TheraSphere	Personalised treatment planning TheraSphere	Clinical advice that standard-dose TheraSphere is not applicable to current UK practice
She 2014¹⁵⁹	SIR-Spheres	TACE	Group imbalances make comparison meaningless (patients were allocated to SIRT if they were not eligible for TACE, e.g. had previously failed on TACE)
Kooby 2010¹⁶⁰	SIR-Spheres	TACE	Study included a more advanced population than in other studies in the NMA of patients eligible for CTTs and there was a baseline imbalance between groups in relation to PVI
Kwok 2014¹⁶¹	SIR-Spheres	No SIR-Spheres	All patients included in the study opted for SIRT, but 16 were ineligible (primarily owing to lung shunt); the study compares those who received it with those who did not
Song 2017¹⁶²	SIR-Spheres	Concurrent chemoradiation therapy	Clinical advice that concurrent chemoradiation therapy is not applicable to current UK practice
Oladeru 2016¹⁶³	SIR-Spheres	External beam radiotherapy	Clinical advice that external beam radiotherapy is not applicable to current UK practice
Rühl 2009¹⁶⁴	SIR-Spheres	High-dose-rate brachytherapy	Clinical advice that high-dose-rate brachytherapy is not applicable to current UK practice
D’Avola 2009¹⁶⁵	SIR-Spheres	No SIRT (combination of conventional or experimental therapies or no therapy)	Comparator was a combination of conventional or experimental therapies or no therapy; conventional therapy patients were not reported separately; therefore, the trial was not informative for the NMA
Carr 2010¹⁶⁶	TheraSphere	TACE	All patients had ECOG performance status of > 2 and therefore were a more advanced population than in other studies in the NMA of patients eligible for CTTs
Kallini 2018¹⁶⁷	TheraSphere	TACE	No OS or PFS outcomes reported and therefore not informative for the NMA
Gabr 2017¹⁶⁸	TheraSphere	TACE	Population of patients who had received a transplant; therefore, not comparable population with other studies in the NMA of patients eligible for CTTs
Riaz 2009¹⁶⁹	TheraSphere	TACE	Group imbalances make comparison meaningless
Biederman 2018¹⁷⁰	TheraSphere	TACE	Patients within Milan criteria, therefore not comparable population to other studies in the NMA of patients eligible for CTTs
Lewandowski 2009¹¹⁸	TheraSphere	TACE	No HRs or KM curves presented, therefore not informative for the NMA. In addition, patients received SIRT or TACE for downstaging; therefore, not comparable population to other studies in the NMA of patients eligible for CTTs
Ahmad 2005¹⁷¹	TheraSphere	TACE	No OS or PFS outcomes reported; therefore, not informative for the NMA
Padia 2017¹⁷²^,¹⁷³	TheraSphere	TACE or DEB-TACE	Mixed population of BCLC A, B and C (70% within Milan criteria); therefore, not informative for the NMA of patients eligible for CTTs
Newell 2015¹⁷⁴	TheraSphere	TACE or DEB-TACE	Mixed population of BCLC B and C patients; therefore, not informative for the NMA of patients eligible for CTTs
Taussig 2017¹⁷⁵	TheraSphere	TACE or DEB-TACE	No OS or PFS outcomes reported; therefore, not informative for the NMA
McDevitt 2017¹⁷⁶	TheraSphere	DEB-TACE	Mixed population of BCLC B and C patients, therefore not informative for the NMA of patients eligible for CTTs. Patients without main PVI could receive DEB-TACE; those with PVI received SIRT and therefore group imbalances
Akinwande 2015¹⁷⁷^,¹⁷⁸	TheraSphere	DEB-TACE	Unclear population, but all patients had PVT; therefore, not informative for the NMA of patients eligible for CTTs
Biederman 2017¹⁷⁹^,¹⁸⁰	TheraSphere	TACE combined with microwave ablation	Clinical advice that TACE combined with microwave ablation is not widely practised in the UK
Padia 2015¹⁸¹	TheraSphere	Ablation, chemoembolisation or BSC	Comparator was a combination of ablation, chemoembolisation and BSC. Chemoembolisation patients were not reported separately; therefore, the trial was not informative for the NMA of patients eligible for CTTs
Radunz 2017¹⁸²	TheraSphere	TACE, radiofrequency ablation or no bridging therapy	Patients were eligible for transplant and received SIRT or TACE for bridging; therefore, not comparable population to other studies in the NMA of patients eligible for CTTs
Salem 2018¹⁰⁸	TheraSphere	N/A	Non-comparative study
Ali 2018¹⁸³	TheraSphere	N/A	Non-comparative study

: N/A, not applicable.

Copyright © Queen’s Printer and Controller of HMSO 2020. This work was produced by Walton et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Bookshelf ID: NBK562663

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Walton M, Wade R, Claxton L, et al. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation. Southampton (UK): NIHR Journals Library; 2020 Sep. (Health Technology Assessment, No. 24.48.) Appendix 7, Lower-priority studies not included in the systematic review of clinical effectiveness or considered for the network meta-analyses (n = 28)
PDF version of this title (3.2M)

Other titles in this collection

Health Technology Assessment

Recent Activity

Clear Turn Off Turn On

Lower-priority studies not included in the systematic review of clinical effecti...
Lower-priority studies not included in the systematic review of clinical effectiveness or considered for the network meta-analyses (n = 28) - Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation
Search strategies for quality-of-life studies - Selective internal radiation the...
Search strategies for quality-of-life studies - Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation
References - Selective internal radiation therapies for unresectable early-, int...
References - Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation
Acknowledgements - Cost and Outcome of BehaviouRal Activation (COBRA): a randomi...
Acknowledgements - Cost and Outcome of BehaviouRal Activation (COBRA): a randomised controlled trial of behavioural activation versus cognitive–behavioural therapy for depression
Summary of product characteristics for the investigational medicinal products - ...
Summary of product characteristics for the investigational medicinal products - Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre, placebo-controlled, randomised controlled trial and cost-effectiveness analysis of a calcium channel blocker (nifedipine) and an alpha-blocker (tamsulosin) (the SUSPEND trial)

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Bookshelf

Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.

Appendix 7Lower-priority studies not included in the systematic review of clinical effectiveness or considered for the network meta-analyses (n = 28)

Views

Other titles in this collection

Recent Activity